Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,541,746 | 3,158,820 | 3,948,122 | 7,562,286 | 9,082,486 |
| Marketable Securities | 135,142 | 104,114 | 149,288 | 225,215 | 344,021 |
| Receivables | 4,786,677 | 4,813,509 | 5,044,528 | 6,446,956 | 7,639,511 |
| Inventories | 8,034,503 | 8,348,096 | 7,299,782 | 7,593,187 | 7,086,481 |
| Other current assets | 1,141,802 | 1,229,661 | 1,303,160 | 1,255,767 | 1,348,691 |
| TOTAL | $16,639,870 | $17,654,200 | $17,744,880 | $23,083,410 | $25,501,190 |
| Non-Current Assets | |||||
| PPE Net | 12,990,180 | 13,729,460 | 12,515,090 | 14,086,920 | 13,666,820 |
| Investments And Advances | 2,388,712 | 2,971,195 | 2,803,542 | 2,938,184 | 3,274,490 |
| Intangibles | 59,109,540 | 66,824,770 | 67,046,810 | 73,214,000 | 74,664,420 |
| Other Non-Current Assets | 2,910,768 | 3,071,045 | 3,177,038 | 3,961,836 | 4,268,640 |
| TOTAL | $77,399,200 | $86,596,470 | $85,542,480 | $94,200,940 | $95,874,370 |
| Total Assets | $94,039,070 | $104,250,700 | $103,287,400 | $117,284,400 | $121,375,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 3,622,997 | 2,534,032 | 2,513,040 | 1,815,538 | 208,238 |
| Accounts payable and accrued liabilities | 3,138,571 | 3,777,895 | 4,804,324 | 4,595,043 | 3,232,077 |
| Other current liabilities | 8,900,384 | 8,890,132 | 9,329,401 | 10,898,250 | 11,862,630 |
| TOTAL | $16,543,040 | $15,960,410 | $18,366,360 | $19,097,000 | $16,667,850 |
| Non-Current Liabilities | |||||
| Long Term Debt | 26,177,750 | 30,887,860 | 29,916,280 | 36,858,620 | 43,364,250 |
| Other Non-Current Liabilities | 5,307,391 | 6,425,812 | 5,977,407 | 6,726,000 | 7,573,621 |
| TOTAL | $31,718,570 | $38,099,630 | $37,896,430 | $47,604,020 | $56,042,240 |
| Total Liabilities | $48,261,610 | $54,060,040 | $56,262,780 | $66,701,010 | $72,710,090 |
| Shareholders' Equity | |||||
| Common Shares | 11,184,920 | 11,568,510 | 12,404,950 | 14,918,740 | 15,680,560 |
| Retained earnings | 7,838,067 | 9,599,301 | 11,404,480 | 13,169,470 | 14,193,120 |
| Other shareholders' equity | 15,528,763 | 17,319,659 | 11,163,800 | 8,318,180 | 3,480,590 |
| TOTAL | $45,777,460 | $50,190,630 | $47,024,570 | $50,583,360 | $48,665,460 |
| Total Liabilities And Equity | $94,039,070 | $104,250,670 | $103,287,350 | $117,284,370 | $121,375,550 |